186 related articles for article (PubMed ID: 22031451)
1. Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome.
Piñana JL; Martino R; Barba P; Bellido-Casado J; Valcárcel D; Sureda A; Briones J; Brunet S; Rodriguez-Arias JM; Casan P; Sierra J
Am J Hematol; 2012 Jan; 87(1):9-14. PubMed ID: 22031451
[TBL] [Abstract][Full Text] [Related]
2. Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children.
Kaya Z; Weiner DJ; Yilmaz D; Rowan J; Goyal RK
Biol Blood Marrow Transplant; 2009 Jul; 15(7):817-26. PubMed ID: 19539213
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients.
Barba P; Piñana JL; Fernández-Avilés F; Perez-Simón JA; Martino R; López-Guerrero E; Valcárcel D; Rovira M; Novelli S; Campos-Varela I; López-Anglada L; Vidal X; López Corral L; Carreras E; Sierra J
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1653-61. PubMed ID: 21586334
[TBL] [Abstract][Full Text] [Related]
6. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
7. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
8. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
10. Relatively favorable outcomes of post-transplant pulmonary function in patients with chronic myeloid leukemia receiving non-myeloablative allogeneic hematopoietic stem cell transplantation.
Lee MY; Chiou TJ; Yang MH; Bai LY; Hsiao LT; Chao TC; Tung SL; Wang WS; Yen CC; Liu JH; Chen PM
Eur J Haematol; 2005 Feb; 74(2):152-7. PubMed ID: 15654907
[TBL] [Abstract][Full Text] [Related]
11. Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning.
Barba P; Martino R; Perez-Simón JA; Fernández-Avilés F; Piñana JL; Valcárcel D; Campos-Varela I; Lopez-Anglada L; Rovira M; Novelli S; Lopez-Corral L; Carreras E; Sierra J
Bone Marrow Transplant; 2012 Oct; 47(10):1343-9. PubMed ID: 22388280
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary function impairment in children following hematopoietic stem cell transplantation.
Wieringa J; van Kralingen KW; Sont JK; Bresters D
Pediatr Blood Cancer; 2005 Sep; 45(3):318-23. PubMed ID: 15747333
[TBL] [Abstract][Full Text] [Related]
13. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
14. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.
Yamamoto W; Ogusa E; Matsumoto K; Maruta A; Ishigatsubo Y; Kanamori H
Am J Hematol; 2014 Sep; 89(9):E138-41. PubMed ID: 24845702
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
18. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation.
Griffith ML; Jagasia MH; Misfeldt AA; Chen H; Engelhardt BG; Kassim A; Savani BN; Survant M; Jagasia SM
Biol Blood Marrow Transplant; 2011 Jan; 17(1):86-92. PubMed ID: 20561594
[TBL] [Abstract][Full Text] [Related]
19. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
[TBL] [Abstract][Full Text] [Related]
20. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties.
Uderzo C; Pillon M; Corti P; Tridello G; Tana F; Zintl F; Nysom K; Galambrun C; Fagioli F; Varotto S; Messina C; Verdeguer A; Urban C; Faraci M; Dini G; Fedeli S; Tichelli A; Rovelli A; Socié G
Bone Marrow Transplant; 2007 Jun; 39(11):667-75. PubMed ID: 17401396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
